Official Title: Combined Platelet TransfusionA Single-arm Open Prospective Non-inferiority Clinical Trial
Status: RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction Due to various factors it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice When ABO-compatible platelets cannot be obtained plasma-reduced platelets platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion
Detailed Description: Combined platelet transfusion is a single-arm open prospective non-inferiority study initiated by researchers Patients with hematological diseases who were admitted to the research unit and applied for platelet transfusion within two years were included in the study after informed consent When the subjects applied for platelet transfusion during the study period ABO homotype platelet transfusion was preferred When there was no ABO homotype platelet in the inventory ABO primary and secondary side compatible combined platelet transfusion was given The study period was 2 years including 15 months of enrollment 6 months of treatment and 3 months of follow-up after the end of the treatment period